Organisation paid for research Program year 2025 Source: CMS Open Payments

Erg Holding Company LLC

Neither a doctor nor a teaching hospital

Research payments

$93,111,970

4,820 payments

Through program year 2025, Erg Holding Company LLC is reported as receiving $93,111,970 in research payments, across 4,820 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $14,622,388 923
2024 Research $12,296,031 697
2023 Research $9,631,287 934
2022 Research $14,340,327 564
2021 Research $17,352,876 542
2020 Research $12,893,250 742
2019 Research $11,975,812 418

Breakdown

Who paid Research payments · program years 2019–2025
  1. Tris Pharma Inc $12,797,731 104 payments
  2. Biogen, Inc. $12,388,666 43 payments
  3. Regeneron Pharmaceuticals, Inc. $7,988,194 120 payments
  4. Sumitomo Pharma America, Inc. $6,168,011 633 payments
  5. Sanofi US Services Inc. $5,703,923 82 payments
  6. Genentech, Inc. $5,015,893 350 payments
  7. Sunovion Pharmaceuticals Inc. $4,973,087 421 payments
  8. AbbVie, Inc. $4,383,830 207 payments
  9. Heron Therapeutics, Inc. $4,315,491 57 payments
  10. Otsuka Pharmaceutical Development & Commercialization, Inc. $4,280,417 58 payments
Studies the money was for Research payments · program years 2019–2025
  1. TRIPHA TRN-228-301 Abdominoplasty P3_CDIMRSX $8,444,347 53 payments
  2. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers $5,320,726 58 payments
  3. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $5,283,267 4 payments
  4. A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers $2,636,768 56 payments
  5. SAR445229 - OX40L mAb - amlitelimab $2,505,840 12 payments
  6. A Double-Blind Randomized Multiple Dose Study of Weight Associated Parameters: SEP?363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects with Schizophrenia Suffering from Metabolic Dysregulation $2,444,429 148 payments
  7. TRIPHA TRN-228-102 Human Abuse Potential P1_CDMPQRSX $2,380,759 14 payments
  8. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $2,045,899 3 payments
  9. TRIPHA TRN-228-302_Bunion_P3 $1,972,624 37 payments
  10. A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia $1,945,004 35 payments
What the money was spent on Research payments · program years 2019–2025
  1. Overhead $5,196,950 17 payments
  2. Patient care $1,495,884 45 payments
  3. Other $3,300 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record